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Abstract
Invasiveness, cellular atypia, and proliferation are hallmarks of malignant gliomas. To effectively target each of these
characteristics, it is important to understand their sequence during tumorigenesis. However, because most gliomas
are diagnosed at an advanced stage, the chronology of gliomagenesis milestones is not well understood. The aim
of the present study was to determine the onset of these characteristics during tumor development. Brain tumor–
initiating cells (BTICs) were established by overexpressing H-RasV12 in normal neural stem/progenitor cells isolated
from the subventricular zone of adult mice harboring a homozygous deletion of the Ink4a/Arf locus. High-grade malig-
nant brain tumors were then created by orthotopic implantation of 105 BTICs into the forebrain of 6-week-old wild-type
mice.Micewere killed everyweek for 5weeks, and tumorswere assessed for cellular atypia, proliferation, hemorrhage,
necrosis, and invasion. All mice developed highly invasive, hypervascular glioblastoma-like tumors. A 100% penetrance
rate and a 4-week median survival were achieved. Tumor cell migration along fiber tracts started within days after
implantation and was followed by perivascular infiltration of tumor cells with marked recruitment of reactive host cells.
Next, cellular atypia became prominent. Finally, mass proliferation and necrosis were observed in the last stage of the
disease. Video monitoring of BTICs in live brain slices confirmed the early onset of migration, as well as the main cell
migration patterns. Our results showed that perivascular and intraparenchymal tumor cell migration precede tumor
mass formation in the adult brain, suggesting the need for an early and sustained anti-invasion therapy.
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Introduction
Malignant gliomas, especially glioblastomas, are most often diagnosed
at an advanced stage. They show a rapid progression and quickly be-
come lethal despite intensive treatment regimens. By the time of initial
surgical evaluation, most malignant gliomas, particularly primary glio-
blastomas, already exhibit pronounced cellular and histologic hetero-
typia, diffuse infiltration into the brain, hemorrhage, and necrosis.
These histopathologic features are the only diagnostic criteria for this
tumor type. Establishing the order of their appearance during tumor
formation can further our understanding of disease progression and
help modulate therapeutic strategies.
Although numerous preclinical models of malignant gliomas have
been established, classic cell line xenograft models display limited
invasiveness and heterogeneity and a variable degree of pathologic
similarity to human gliomas [1–3]. Recently, new animal models
were developed using glioblastoma stem cells isolated from human
surgical specimens [4]. Other models that have genetically engineered
neural stem cells (NSCs) and progenitor cells (NPCs) were developed
[5,6]. These new models show greater similarity to human tumors [2].
However, despite improvements, long latency, variable penetrance
rate, technical complexity, and/or low reproducibility are still, in many
cases, precluding the systematic analysis of the characteristics of early
stage glioblastoma [1].
Furthermore, to allowmonitoring of disease progression, glioblastoma
models should exhibit aggressive tumor formation in the adult brain
in the context of an immunocompetent microenvironment. Using brain
tumor–initiating cells (BTICs) genetically induced from adult murine
NSCs, we established a syngeneic mouse model that consistently and
faithfully recapitulates the hallmark features of glioblastomas. Our analy-
sis of tumor progression in this model indicates that the migration of
solitary tumor cells into the normal brain is the earliest event in disease
progression, followed by host response, appearance of atypical cells, and
mass formation.
Materials and Methods
Animal Experiments
All experiments were performed in accordance with the animal care
guidelines of Keio University.
Neural Stem/Progenitor Cell Culture
Six-week-old male Ink4a/Arf null C57BL/6 mice (B6.129-
Cdkn2atm1Rdp; National Cancer Institute, Frederick, MD) were
euthanized with a lethal dose of pentobarbital. Brains were extracted,
and the subventricular zone (SVZ) was isolated by microdissection,
washed, trypsinized, and then mechanically dissociated. Primary NSCs/
NPCs were maintained as sphere culture in Dulbecco modified Eagle
medium (DMEM)/F12 (Sigma, St Louis, MO) supplemented with
20 ng/ml epidermal growth factor (EGF; PeproTech, Rocky Hill,
NJ), 20 ng/ml basic fibroblast growth factor (PeproTech), B27 sup-
plement without vitamin A (Invitrogen, Carlsbad, CA), 200 ng/ml
heparan sulfate, 100 U/ml penicillin, and 100 ng/ml streptomycin
(Nacalai Tesque, Kyoto, Japan) at 37°C in 5%CO2/95% humidified air.
Retroviral Vector Constructs and Preparation of
Retroviral Supernatants
Human H-RasV12 cDNA [7] (kindly provided by P. P. Pandolfi)
was cloned into the retroviral vector pMXs-IG (kindly provided by
T. Kitamura). The empty vector was used as a control. pMXs vectors
were transfected into Plat-E packaging cells [8] using FugeneHD (Roche
Diagnostics, Mannheim, Germany). Medium was replaced once after
24 hours, and viral supernatants were collected and filtered with 0.45-μm
cellulose acetate filters (Iwaki, Kyoto, Japan) 48 hours after transfection.
Supernatants were centrifuged at 12,000g for 6 hours at 4°C, and the
viral pellet was resuspended in small volumes of NSC culture medium.
Brain Tumor–Initiating Cells
Primary Ink4a/Arf null NSC/NPCs were infected with retroviral
supernatants. The resulting mixture of GFP-positive and GFP-negative
cells, termed Ras-NSCs hereafter, was cultured as spheres and used for
implantation after one passage. None of the Ras-NSCs used showed
any phenotypic change during culture.
Tumorsphere Culture
Primary tumors were dissected from the mouse brains and subjected
to mechanical and enzymatic dissociation. GFP-positive cells were
sorted from single-cell suspensions by flow cytometry (FACSVantage;
Becton-Dickinson, Franklin Lakes, NJ) and cultured in NSC culture
medium as tumorspheres. In all experiments, tumorspheres were disso-
ciated to obtain a single-cell suspension before use.
Differentiation Assays
Ras-NSCs were cultured on dishes coated with poly-L-lysine (Sigma)
in DMEM/F12 supplemented with 10% fetal calf serum for 2 weeks
and then analyzed by immunocytochemistry.
Orthotopic Transplants
Female C57BL/6 mice aged 6 to 8 weeks were anesthetized and
placed into a stereotactic apparatus equipped with a z axis (David Kopf
Instruments, Tujunga, CA). A small hole was bored into the skull 2.0mm
lateral to the bregma using a dental drill. One hundred thousand viable
cells in 2 μl of Hank’s balanced salt solution were injected into the right
hemisphere 3 mm below the surface of the brain using a 10-μl Hamilton
syringe with an unbeveled 30-gauge needle. The injection was performed
over 2 minutes, with an additional 2-minute pause before removing the
syringe. The hole was sealed with bone wax, and the scalp was closed
using a 9-mm autoclip applicator. Animals were followed daily for the
development of neurologic deficits.
Immunohistochemistry/Immunocytochemistry
For histologic analysis, tissues were fixed overnight with 4% para-
formaldehyde, embedded in paraffin and then sectioned at a thickness
of 4 μm. Deparaffinized sections were stained with mouse monoclonal
antibody to nestin, O4 (Millipore, Billerica, MA), rat antimouse mono-
clonal antibody to F4/80 (Serotec, Oxford, United Kingdom), and rabbit
polyclonal antibody to GFP (Santa Cruz Biotechnology, Santa Cruz,
CA), Ki67 (NeoMarkers, Fremont, CA). Immune complexes were de-
tected with the use ofM.O.M. Immunodetection Kit (Vector Laboratories,
Burlingame, CA) (nestin, O4) or Histofine (Nichirei Biosciences, Tokyo,
Japan) (F4/80, GFP, Ki67), and ImmPACTDAB (Vector Laboratories).
For immunocytochemistry, spheres/cells were fixed with 4% para-
formaldehyde and stained with mouse monoclonal antibody to nestin,
O4 (Millipore), Tuj-1 (Covance, Princeton, NJ), and rabbit polyclonal
antibody to GFAP (DAKO, Carpinteria, CA), followed by Alexa 568–
conjugated antimouse or antirabbit IgG secondary antibody. CD44 was
stained with phycoerythrin-conjugated antimouse CD44 (clone IM7;
BioLegends, San Diego, CA). Nuclei were counterstained with 4′,6-
diamino-2-phenylindole (DAPI, VectaStain; Vector Laboratories). For
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coronal brain slices, brains were fixed with 4% paraformaldehyde and
sectioned at 100 μm using a Leica VS1200 vibratome (Leica, Wetzlar,
Germany). Slices were then washed and covered with VectaStain con-
taining DAPI (Vector Laboratories). Images were acquired using a
BZ9000 inverted fluorescent microscope (Keyence, Osaka, Japan) and
digitally processed with the Keyence Analysis Software. Discrete tumor
cells were identified on coronal slice images using the Neurolucida
software (MBF Bioscience, Williston, VT).
Explant Culture of Coronal Brain Slices
Brains of tumor-implanted C57BL/6 mice were dissected manu-
ally and cut into 150-μm coronal slices using a Leica VS1200 vibratome
(Leica). Explants were cultured on Millicell-CM culture plate inserts
(Millipore) in six-well glass-bottom plates. Slices were maintained in
the NSC culture medium (NSM) described previously, at 37°C in
5%CO2/95%humidified air. Serial images were acquired every 15min-
utes with a fluorescence microscope (TE2000-E; Nikon, Tokyo, Japan)
and processed with MetaMorph imaging software (Universal Imaging
Corp, Downingtown, PA).
Magnetic Resonance Imaging
The magnetic resonance (MR) images were acquired on a 1.5-T
MR unit (MRmini SA; DS Pharma Biomedical, Osaka, Japan). T1-
weighted imaging was performed using the following parameters
(repetition time/echo time = 500/9 milliseconds, field of view = 20 mm,
matrix = 128 × 128, slice thickness = 2mm).Micewere anesthetizedwith
pentobarbital and injected subcutaneously with 0.5 mM/kg Magnevist
(Bayer Pharmaceuticals, Leverkusen, Germany).
Statistical Analysis
Survival analysis was performed using JMP9 (SAS Institute, Cary, NC).
Results
Genetically Modified Adult Neural Stem/Progenitor Cells
Form Highly Aggressive, Malignant Brain Tumors in
Immunocompetent Mice
To establish BTICs, we used two oncogenic events commonly ob-
served in glioblastoma: deletion of the INK4/ARF locus and aberrant
Ras activation. Alterations in the INK4/ARF locus can be found in
approximately 50% of glioblastomas and contribute to tumorigenesis
through the inactivation of the tumor suppressor gene [9,10]. Aberrant
Ras activation, although seldom because of oncogenic mutations, con-
tributes to malignant gliomas by deregulation of the RTK/Ras path-
way [11,12], which is observed in more than 80% of glioblastomas
[9]. A combination of Ink4a/Arf deletion and K-Ras overexpression
in neonatal NSCs/NPCs was reported to form high-grade malignant
brain tumors in mice [13], as did infection of neonatal Ink4a/Arf null
mice with RCAS-KRas [14].
To avoid the context of developmental plasticity and signaling,
we established our model using NSC/NPCs from adult Ink4a/Arf
null mice. The NSC/NPCs were genetically modified by retroviral
transduction with the constitutively active H-RasV12. Infected cells
(Ras-NSCs) were GFP-, nestin-, and CD44-positive (Figure 1, A and
B) and formed neurospheres from single cells (Figure 1C ). They ex-
hibited cellular and nuclear heterotypia (Figure 1D) and were able to
differentiate into astrocytes, neurons, and oligodendrocytes after cul-
ture in growth factor–free, serum-supplemented medium (Figure 1E).
Furthermore, Ras-NSCs also maintained the migratory capability of
NSCs, as shown by their response to several known chemoattractants
(Figure W1A).
Together, these results indicate that the NSC/NPCs retain their
stem-like characteristics, including sphere-forming activity and triline-
age differentiation ability, even after oncogenic induction.
To confirm whether Ras-NSCs can act as BTICs, we implanted 105
cells into the forebrain of immunocompetent mice, before their com-
plete in vitro transformation. In contrast to NSC/NPCs transduced
with only GFP, which did not form tumors (Figure 1H and Fig-
ure W1B), Ras-NSCs formed highly aggressive, hemorrhagic brain
tumors (Figure 1, F and G) with a penetrance rate of 100% and a me-
dian survival of 4 weeks (Figure 1H). This result suggests that in vivo
modulation of the Ras-NSCs further enhanced their malignant poten-
tial. As further support for this assumption, GFP-positive cells isolated
from primary tumors (tumorspheres) were also serially transplantable
and formed highly invasive and lethal tumors (Figure 1, I and J). Im-
portantly, as few as 100 cells could form secondary tumors, suggesting
a very high tumor-initiating ability.
Chronological Analysis of Tumor Progression Reveals an Early
Onset of Tumor Cell Migration
Primary tumors closely resembled the pathologic and immuno-
phenotypical features of human grade 4 glioma, such as hemorrhage
and necrosis (Figure 2A), pronounced cell proliferation (Figure 2B),
and the expression of primitive marker nestin (Figure 2C ) and of
CD44 (Figure 2D), reported positive in the mesenchymal subtype of
glioblastoma [9]. Tumors also exhibited high cellular heterotypia (Fig-
ure 2, E and F), giant cells (Figure 2G ), pseudopallisading (Figure 2H),
and marked infiltration of the surrounding brain (Figure 2I ).
To identify the onset of the main histopathologic features during tu-
mor formation, 15 mice were implanted with Ras-NSCs and then
killed and analyzed at 1-week intervals (n = 3 × 5 weeks). During the
first week, GFP-positive cells were clearly identifiable along the injec-
tion trajectory (Figure 3A). There was no mass formation or obvious
hemorrhage; however, some single cells had started to migrate along
fiber tracts, either laterally along the external capsule (Figure 3B) or
medially toward the corpus callosum (Figure 3C ), reaching as far as
400 μm into the normal brain (FigureW1C ). During the second week,
there was still no mass formation (Figure 3D). Most of the blood vessels
close to the injection tract showed prominent encapsulation (Figure 3,
D and E). This perivascular cuffing consisted of very few tumor cells, as
confirmed by GFP staining (Figure 3F), and was mostly an accumula-
tion of host cells, including macrophages and microglia (Figures 3G
and W1D). Blood vessel encasement by reactive cells continued into
the third week (Figure 3, H and I ). Giant cells also appeared at this
stage, with overall cellular heterotypia markedly increased (Figure 3J).
Mass formation became obvious after 4 weeks, with tumors growing
rapidly, including hemorrhage and necrosis (Figure 1F and Figure 2A),
and quickly becoming lethal (Figure 1H).
Ras-NSCs Exhibit Multiple Invasion Patterns
As the invasion of tumor cells into the normal brain seemed to be
the first notable event of tumor formation, we further investigated
the onset and patterns of migration. Tumor cells spread mainly along
blood vessels, fiber tracts, or into the subarachnoid space. Dissemina-
tion along blood vessels started during the first week after implantation,
with tumor cells first eliciting host response, but then completely en-
casing the blood vessels during the mass growth stage (Figures 4A and
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W1E). Migration along fiber tracts was noticed as early as 2 days after
implantation, showing not only single-cell movement but also an inva-
sion pattern suggestive of collective cell migration [15] (Figure 4B). A
third pattern consisted of tumor cells reaching the subarachnoid space
and spreading over the brain surface (Figure 4C).
Solitary Ras-NSCs Invade Normal Parenchyma in
Live Brain Slices
To confirm the migration of solitary cells during the early days
after implantation, a new series of Ras-NSC–injected mice were
killed every 2 days during the first week, brains were extracted,
Figure 1. RAS-NSC spheres express GFP (green) and nestin (red) (A) and GFP (green) and CD44 (red) (B). Blue indicates nuclear counterstain
DAPI. (C) Sequential pictures of a single Ras-NSC cell giving rise to a sphere in a soft-agar sphere formation assay. Time denotes days:hours:
minutes. (D) Ras-NSCs have different sizes and morphologies. HE indicates hematoxylin-eosin staining. (E) Ras-NSCs cultured in serum-
supplemented medium become positive for GFAP, Tuj-1, and O4. (F) Ras-NSCs form hemorrhagic tumors on orthotopic implantation.
Mouse brain, 28 days after implantation, macroscopic coronal view at the bregma level. (G) Tumors show ring enhancement on a gadolinium-
enhanced MR image. Coronal view, Gd T1-weighted image. (H) All Ras-NSC–injected mice (blue) developed brain tumors and died within
50 days after implantation. Mice injected with NSCs transduced with GFP only (control, red) did not form any tumors. Kaplan-Meier survival
analysis, n=5. (I) GFP-positive cells isolated fromprimary tumors (tumorspheres, TS) formhighly invasive secondary tumors. Discrete single
tumor cells or small groups of cells are marked with pink. (J) Only 100 tumor cells are required to form secondary tumors. Kaplan-Meier
survival analysis of mice injected with 105, 104, 103, 102, and 10 tumor cells, n= 6 for each group. Scale bars, 20 μm (C); 50 μm (A, B, D, E).
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Figure 3. Chronological analysis of tumor progression. (A) Small groups of tumor cells along the injection tract, whole mount slice (HE
staining), at day 7 after implantation. (B, C) GFP-positive cells, marked with an asterisk, can be observed along fiber tracts, away from the
injection route. (D, E) Fourteen days after implantation, blood vessels around the injection route are encased by cells. A serial slice
shows that only a few cells are GFP-positive (F), whereas many are microglia (G) (F4/80 staining). (H, I) At day 21, blood vessel encase-
ment is still prominent. (J) Atypic cells appear around this time. Scale bars, 50 μm (E, F, G); 100 μm (B, C, I, J); and 1000 μm (A, H).
Figure 2. Histopathologic analysis of primary tumors. (A) Hemorrhage and necrosis (HE staining). Insert, whole-mount view. (B) Tumors
exhibit a high proliferation index (Ki67 staining). Insert, whole-mount view. (C) Tumors are nestin- and (D) CD44-positive. Shown also are
spindle-shaped (E), alveolar-like (F), and giant (G) cells. (H) Pseudopallisading. (I) Blood vessel encasement by tumor cells in the normal
brain parenchyma close to the tumor border. Scale bars, 20 μm (F); 50 μm (E, I); 100 μm (A, B, C, G, H); and 1000 μm (D).
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and coronal slices were cultured under video observation. Time-lapse
monitoring confirmed single-cell migration at this very early stage
after implantation. In contrast to NSCs without Ras activation, which
did not spread from the injection site (Video W3), Ras-NSCs were
highly motile as solitary infiltrative cells, exhibited repeated extension
and retraction of leading processes, and sometimes reversed direction
(Figure 5 and Video W1). Furthermore, once one leading cell migrated
along a specific route without turning around, several cells followed it,
establishing an infiltration path (Figure 6 and Video W2). The infiltra-
tive ability of Ras-NSCs was maintained even during the later stages of
tumor formation, with single cells still migrating into the normal brain
in addition to the expansion of the tumor border (Video W4).
Discussion
We have established a syngeneic mouse model of a highly invasive,
hypervascular, serially transplantable glioblastoma-like tumor.
One of the key features of this model is a cellular and histologic het-
erogeneity highly resembling that of human glioblastoma. Glioblastoma
heterogeneity has traditionally been attributed to a gradual accumulation
of diverse genetic events [16,17]. Recently, the existence of glioma stem
cells [18], which can give rise to different types of daughter cells, has
been proposed as another cause of cellular diversity [19,20].
Our model uses two genetic switches: Ras overexpression and Ink4a/
Arf deletion. However, implantation of the NSC/NPC population before
complete in vitro transformation is intended to allow further genetic and/or
epigenetic events to occur in vivo, a process that is thought to occur during
spontaneous gliomagenesis in human patients. Despite being genetically
modified, these cells retain some of the properties of normal NSC/NPCs
as shown by their ability to differentiate in vitro despite Ras overexpression.
Retaining normal stem cell features also provides Ras-NSCs with inherent
motility and susceptibility to chemical cues from the environment [21–23].
Furthermore, NSCs’ characteristics might enhance tumorigenic ability
and probably also contribute, as intended, to the cellular heterogeneity.
The use of adult NSC/NPC as initial cells complements similar models
that rely on neonatal NSC/NPCs [13], ES cells [24], or model the pro-
gression of low grade astrocytoma to secondary glioblastoma [12]. In the
future, it will be interesting to isolate different types of cells, such as giant
cells, from live tumor-bearing brain slices and to analyze their genetic
signature, differentiation status, and clonal tumorigenic potential.
Another merit of our model is its predictable and reproducible
growth pattern. After orthotopic implantation, genetically modified
adult NSC/NPCs stably form short-latency tumors. In vivo growth
characteristics showed remarkable consistency and allowed detailed
histopathologic analysis from the early stages of tumor development
and throughout the course of the disease.
Figure 4. Invasion patterns of Ras-NSCs. (A) Left panel: A few GFP-positive tumor cells are found next to a blood vessel in the brain of a
mouse killed 7 days after implantation. Middle panel: A few tumor cells and a group of host-derived cells surround a blood vessel at
day 14. Right panel: A blood vessel in normal brain is surrounded by tumor cells at day 28. Scale bars, 50 μm. (B) GFP-positive tumor
cells migrate along fiber tracts toward the midline. Coronal brain slice, day 2 after implantation, nuclei counterstained with DAPI.
CC indicates corpus callosum; EC, external capsule; LV, lateral ventricle. Scale bar, 100 μm. (C) GFP-positive tumor cells have reached
the subarachnoid space. Coronal brain slice, day 18 after implantation. Scale bar, 200 μm.
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The key finding of our analysis was that Ras-NSCs migrated along
fiber tracts, blood vessels, and into the subarachnoid space and that
migration along fiber tracts and blood vessels began long before tumor
mass formation. The three main dissemination routes observed in our
study are consistent with classic reports based on postmortem analysis of
human gliomas [25,26], validating this model as a tool for invasion anal-
ysis. Onset of migration has usually been linked to the lack of oxygen
and nutrients that is inherent to tumor growth. Our results show that
neoplastic cells are able to initiate invasion even in the absence of such
environmental pressure. Movement along fiber tracts might be the result
of an affinity for stiff structures, as has been shown for breast tumor
cells [27]. It might also reflect a pattern of collective cell migration, with
paths of least mechanical resistance created by individual “leader” cells,
as seen with invasive cancer cells such as fibrosarcoma [28].
Intraparenchymal movement of the tumor cells might also be the
result of chemoattractant cues from the SVZ stem cell niche or the
environment. Indeed, our Ras-NSCs responded to addition of EGF
in chemotaxis assays; however, their poor response to several other
Figure 6. Tumor cells form infiltration paths in the normal brain parenchyma. Sequential pictures of GFP-positive tumor cells moving
within a brain slice in culture. Arrowheads indicates gradual formation of infiltration paths. Time denotes days:hours:minutes. Scale bar,
30 μm.
Figure 5. Tumor cells moving along the wall of the lateral ventricle. Sequential pictures of GFP-positive tumor cells moving within a brain
slice in culture. Arrowhead indicates cell changing direction. Time denotes days:hours:minutes. Scale bar, 30 μm.
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known chemoattractants suggests that in vivo invasion may be regu-
lated by a yet unknown factor, might depend on the brain matrix for
modulation, or might require a combination of chemokines.
Affinity for blood vessels seems to be independent of oxygen gradients
because cultured brain slices do not have blood circulation but could be
caused by endothelium-secreted factors or cues from perivascular niches.
Interestingly, injection of rat cells into neonatal rat brains has also been
reported to result in prompt initiation of invasion; however, the im-
mortalized glioma cells migrated exclusively along blood vessels [29].
Performing the analysis with primary cells in a syngeneic model has
allowed us to explore intraparenchymal infiltration, which has not been
well studied in live systems. Video monitoring of GFP-expressing cells in
brain slices confirmed that solitary Ras-NSCs started migrating within
days of implantation. The first cells to leave the injection site exhibited
relatively random dynamics, stopping, and turning, as if responding to
environmental cues. However, once these leading cells chose a route,
they established a path for other cells. Although it is still unclear whether
these early migrating cells are able to survive and proliferate at the distant
sites they reach, the paths that they create may serve as dissemination
routes during later stages or as recurrence sites during treatment. Isolat-
ing such “leader” cells from brain slices and identifying their charac-
teristic markers, as well as the molecular base of their path-forming
capability will likely advance not only prognostic determination but
also treatment strategies.
Current anti-invasion therapies for malignant gliomas include targeting
the tumor cell–matrix interaction, such as the use of integrin antagonists
and MMP inhibitors, have shown promise in vitro, and some are now in
clinical trials [30]. However, intrinsic characteristics of glioma cells must
also be considered. Although all malignant glioma cells are believed to
have an infiltrative ability, a transient or permanent mesenchymal pheno-
type or the presence of such a subgroup in a tumor has been reported to
result in increased invasiveness. Targeting this phenotype or preventing
new cells from acquiring it through the use of inhibitors of the epithelial-
mesenchymal transition could be another therapeutic strategy, which we
also plan to test in our model. Taken together, our results highlight a
pronounced intravascular, intraparenchymal, and subpial tumor cell
migration preceding mass formation in the adult brain, suggesting the
need for early and sustained anti-invasion therapy.
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Supplemental Information
Methods
In vitro migration assay. Random cell migration in response to sev-
eral chemoattractants was quantified using the agarose drop assay [1].
Neural stem cells transduced with GFP only or Ras-NSCs were sus-
pended in DMEM/F12 containing B27 supplemented with 0.3%
low-melting point agarose (Sigma) at a density of 107 cells/ml. Drops
of 1.5 μl of this suspension were placed at the center of poly-L-lysine–
coated glass-bottom 24-well plates and then maintained at 4°C for
15 minutes until the agarose hardened. Drops were then covered with
either DMEM/F12 containing B27 alone (control), or supplemented
with the following factors: EGF, FGF, PDGFB, VEGF, CXCL12,
IGF-1 at 50 ng/ml, 20 ng/ml IL-6, NSM and 10% fetal calf serum,
each added to two wells. Time-lapse recording of the cells migrating
out of the agarose drop was performed for 46 hours with a fluorescence
microscope (TE2000-E; Nikon). Experiments were performed in du-
plicate and migration was quantified using the MetaMorph software,
by measuring the migrated distance of 15 leading cells from at least
three independent wells. Data were analyzed for statistical significance
by the Wilcoxon signed-rank test, and P < .01 was considered statisti-
cally significant.
Quantification of pathology samples. For the chronological weeks 1
to 4 analysis, at least two paraffin slices from at least two different mice
were used for quantification for each time point. For quantification of
invasion, the distance between the tumor margin (or margin of the big-
gest group of tumor cells for early stage) and five invasive tumor cells/
sample was measured from GFP-stained paraffin slices. For microglia
accumulation, the percentage of the F4/80–positive area in the injected
hemisphere was calculated. Tumor cells associated with blood vessels
within the normal brain were counted from GFP-stained slices. All
measurements were performed with the Keyence analysis software.
Results were expressed as mean ± SEM.
Reference
[1] Varani J, Orr W, and Ward PA (1978). A comparison of the migration patterns
of normal and malignant cells in two assay systems. Am J Pathol 90, 159–172.
Figure W1. (A) In the in vitro migration assay, NSCs transduced with GFP only respond to CXCL12, IL-6, and NSM, whereas Ras-NSCs
are attracted by EGF and serum. CXCL12 indicates chemokine (C-X-C motif) ligand 12; EGF, epidermal growth factor; FGF, basic fibro-
blast growth factor; IGF-1, insulin-like growth factor 1; IL-6, interleukin 6; PDGFB, platelet-derived growth factor β; VEGF, vascular en-
dothelial growth factor. *P < .01 compared with control group. (B) NSCs transduced with GFP only do not form tumors when implanted
into syngeneic mice. Left panel: Brain slice showing few residual cells at the injection site 11 days after implantation of 105 cells. Right
panel: At day 14 after implantation, no residual cells can be identified. (C) Chronological quantification of solitary tumor cells infiltration
into the normal brain. Invasion of Ras-NSCs is prominent from the first week after implantation. (D) Starting the second week after
implantation, F4/80–positive microglia start to accumulate around the injection site. There is no obvious microglia accumulation after
injection of phosphate-buffered saline only. (E) GFP-positive tumor cells associated with blood vessels drastically increase in number
during the final stage of tumor formation.
Video W1. GFP-positive tumor cells moving along the wall of the
lateral ventricle within a brain slice in culture. Time denotes days:
hours:minutes. Scale bar, 30 μm. All files are in AVI format. It is
preferable to use QuickTime for replaying all movies.
Video W2. GFP-positive tumor cells form infiltration paths in the nor-
mal parenchyma of a brain slice in culture. Time denotes days:
hours:minutes. Scale bar, 30 μm.
Video W3. GFP-positive NSCs move within the group of cells at
the injection site but do not infiltrate into the normal brain. Time
denotes days:hours:minutes. Scale bar, 50 μm.
Video W4. At the stage when a tumor mass has been formed,
tumor both expands and infiltrates the surrounding brain. Time de-
notes days:hours:minutes. Scale bar, 100 μm.
